Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary
暂无分享,去创建一个
J. Wedzicha | M. Decramer | F. Martinez | M. Nishimura | P. Frith | A. Anzueto | R. Rodríguez-Roisín | G. Criner | J. Bourbeau | B. Celli | Rongchang Chen | D. Halpin | M. V. Lopez Varela | N. Roche | D. Sin | Dave Singh | R. Stockley | J. Vestbo | A. Agustí | C. Vogelmeier | L. Fabbri | P. Barnes
[1] Michel Wolff,et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. , 2017, The Cochrane database of systematic reviews.
[2] R. Wood‐Baker,et al. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial , 2010, BMJ : British Medical Journal.
[3] R. Stockley,et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. , 2000, Chest.
[4] Charlotte Suppli Ulrik,et al. Effect of tele health care on exacerbations and hospital admissions in patients with chronic obstructive pulmonary disease: a randomized clinical trial , 2015, International journal of chronic obstructive pulmonary disease.
[5] B. Celli,et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. , 2015, American journal of respiratory and critical care medicine.
[6] D. Mannino,et al. Lung function impairment, COPD hospitalisations and subsequent mortality , 2011, Thorax.
[7] N. Chavannes,et al. Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial , 2014, BMJ : British Medical Journal.
[8] P. Lange,et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.
[9] H. Reddel,et al. American Thoracic Society , 2001 .
[10] D. Mannino,et al. Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008. , 2012, American journal of respiratory and critical care medicine.
[11] C. Cates,et al. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.
[12] R. Cumming,et al. Use of inhaled and oral corticosteroids and the long-term risk of cataract. , 2009, Ophthalmology.
[13] Christopher E Brightling,et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. , 2012, American journal of respiratory and critical care medicine.
[14] B. Lipworth,et al. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.
[15] P. Calverley,et al. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial , 2005, Thorax.
[16] M. Cazzola,et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis , 2015, European Respiratory Review.
[17] F. Martinez,et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.
[18] V. Tirlapur. Relationship of ventricular ectopy to nocturnal oxygen desaturation in patients with chronic obstructive pulmonary disease. , 1985, The American journal of medicine.
[19] D. Jarvis,et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. , 2011, American journal of respiratory and critical care medicine.
[20] Ø. Borgan,et al. Lung transplantation in patients with chronic obstructive pulmonary disease in a national cohort is without obvious survival benefit. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[21] K. Chapman,et al. Physician perceptions and management of COPD. , 1993, Chest.
[22] G. Criner,et al. Home non-invasive ventilation use following acute hypercapnic respiratory failure in COPD. , 2014, Respiratory medicine.
[23] S. Rennard,et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[24] B. Celli,et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.
[25] G. Kirk,et al. HIV-associated obstructive lung diseases: insights and implications for the clinician. , 2014, The Lancet. Respiratory medicine.
[26] F. Maltais,et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. , 2002, American journal of respiratory and critical care medicine.
[27] D. Postma,et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. , 1999, The New England journal of medicine.
[28] N. Zhong,et al. Positive benefits of theophylline in a randomized, double‐blind, parallel‐group, placebo‐controlled study of low‐dose, slow‐release theophylline in the treatment of COPD for 1 year , 2006, Respirology.
[29] N. Maimon,et al. The Association Between Hospital Readmission and Pulmonologist Follow-up Visits in Patients With COPD. , 2015, Chest.
[30] T. Omachi,et al. Influence of anxiety on health outcomes in COPD , 2010, Thorax.
[31] G. Marks,et al. Tuberculosis and chronic respiratory disease: a systematic review. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[32] Meilan K. Han,et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. , 2014, The New England journal of medicine.
[33] E. Wouters,et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. , 1993, The American review of respiratory disease.
[34] Niels H Chavannes,et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. , 2009, American journal of respiratory and critical care medicine.
[35] A. Melani. Long-acting muscarinic antagonists , 2015, Expert review of clinical pharmacology.
[36] P. Calverley,et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.
[37] C. Bullen,et al. Electronic cigarettes for smoking cessation and reduction. , 2014, The Cochrane database of systematic reviews.
[38] E. Salpeter,et al. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. , 2004, Chest.
[39] A. Torres,et al. Guidelines for the management of adult lower respiratory tract infections , 2005, European Respiratory Journal.
[40] C. Husten,et al. How to help your patients stop smoking. , 1978, American family physician.
[41] M. Miravitlles,et al. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis , 2011, European Respiratory Journal.
[42] D. Lawlor,et al. Association of birth weight with adult lung function: findings from the British Women’s Heart and Health Study and a meta-analysis , 2005, Thorax.
[43] Dennis Emralino Dantic,et al. A critical review of the effectiveness of ‘teach-back’ technique in teaching COPD patients self-management using respiratory inhalers , 2014 .
[44] J. Bourbeau,et al. Clinical Relevance of Fixed Ratio vs Lower Limit of Normal of FEV1/FVC in COPD: Patient-Reported Outcomes From the CanCOLD Cohort , 2015, The Annals of Family Medicine.
[45] R. Casaburi,et al. Phenotype of Spirometric Impairment in an Aging Population. , 2016, American journal of respiratory and critical care medicine.
[46] I. Smith,et al. The Effects of Withdrawing Long-Term Nocturnal Non-Invasive Ventilation in COPD Patients , 2010, COPD.
[47] J. Soriano,et al. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. , 2014, Chest.
[48] S. Glantz,et al. E-cigarettes and smoking cessation - Authors' reply. , 2016, The Lancet. Respiratory medicine.
[49] B. Make,et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.
[50] Y. Hasegawa,et al. COPD and disease-specific health status in a working population , 2013, Respiratory Research.
[51] M. Polkey,et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (The BeLieVeR-HIFi trial): study design and rationale , 2014, Thorax.
[52] J. Wedzicha,et al. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis , 2003, BMJ : British Medical Journal.
[53] O. Keene,et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.
[54] W. MacNee,et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.
[55] T. Lasserson,et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.
[56] J. Bourbeau,et al. Tiotropium for stable chronic obstructive pulmonary disease , 2005 .
[57] John Connett,et al. Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.
[58] Dave Singh,et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. , 2015, Respiratory medicine.
[59] Michael C. Fiore,et al. A Clinical Practice Guideline for Treating Tobacco Use and Dependence A US Public Health Service Report , 2000 .
[60] M. Martínez-García,et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.
[61] M. Cazzola,et al. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. , 2010, Pulmonary pharmacology & therapeutics.
[62] P. Jones,et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease , 1999, Thorax.
[63] F. Martinez,et al. The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery. , 2011, American journal of respiratory and critical care medicine.
[64] K. Rabe,et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. , 2016, American journal of respiratory and critical care medicine.
[65] J. Soriano,et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. , 2010, American journal of respiratory and critical care medicine.
[66] T. Seemungal,et al. COPD exacerbations: defining their cause and prevention , 2007, The Lancet.
[67] R. Murray,et al. Smoking cessation in chronic obstructive pulmonary disease. , 2009, Respiratory medicine.
[68] C. Jiang,et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study , 2007, The Lancet.
[69] D. Niewoehner,et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. , 2012, Respiratory medicine.
[70] Stefan Störk,et al. "GOLD or lower limit of normal definition? a comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study" , 2012, Respiratory Research.
[71] R. Casaburi,et al. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients , 2008, International journal of chronic obstructive pulmonary disease.
[72] F. Martinez,et al. Effect of Ro fl umilast and InhaledCorticosteroid / Long-Acting b 2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations ( RE 2 SPOND ) A Randomized Clinical Trial , 2016 .
[73] T. Seemungal,et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.
[74] S. K. Chhabra,et al. Chronic obstructive pulmonary disease and cardiovascular disease. , 2006, The Indian journal of chest diseases & allied sciences.
[75] Robert West,et al. Association between electronic cigarette use and changes in quit attempts, success of quit attempts, use of smoking cessation pharmacotherapy, and use of stop smoking services in England: time series analysis of population trends , 2016, British Medical Journal.
[76] D. Price,et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study , 2014, Respiratory Research.
[77] F. Herrmann,et al. Can early introduction of specialized palliative care limit intensive care, emergency and hospital admissions in patients with severe and very severe COPD? a randomized study , 2014, BMC Palliative Care.
[78] F. Maltais,et al. Aerobic and strength training in patients with chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.
[79] F. Martinez,et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial , 2015, The Lancet.
[80] J. Brophy,et al. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. , 2012, Chest.
[81] S. Johnston,et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. , 2006, American journal of respiratory and critical care medicine.
[82] R. D. de Haan,et al. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. , 2010, Journal of aerosol medicine and pulmonary drug delivery.
[83] Steven Piantadosi,et al. Patients at high risk of death after lung-volume-reduction surgery. , 2001, The New England journal of medicine.
[84] Edwin K Silverman,et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.
[85] J. Krieger,et al. Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome. , 1988, The American review of respiratory disease.
[86] James D. Chalmers,et al. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. , 2013, Annals of the American Thoracic Society.
[87] N. Hill,et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. , 1995, American journal of respiratory and critical care medicine.
[88] L. Davies,et al. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial , 1999, The Lancet.
[89] Steven Piantadosi,et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.
[90] A. Rahmel,et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[91] R. Casaburi,et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. , 2005, Chest.
[92] J. Maurer. Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone-Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial , 2008 .
[93] J. Wedzicha,et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial , 2010, Respiratory research.
[94] J. E. Hansen,et al. Counterpoint: Is an increase in FEV₁ and/or FVC ≥ 12% of control and ≥ 200 mL the best way to assess positive bronchodilator response? No. , 2014, Chest.
[95] D. Mannino,et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. , 2009, American journal of respiratory and critical care medicine.
[96] F. Martinez,et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials , 2009, The Lancet.
[97] T. Lasserson,et al. Lung volume reduction surgery for diffuse emphysema. , 2000, The Cochrane database of systematic reviews.
[98] K. Porter. Hospital and Medical School Planning , 1962 .
[99] C. Marquette,et al. Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial. , 2016, JAMA.
[100] J. M. FitzGerald,et al. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. , 1997, Archives of internal medicine.
[101] David O Wilson,et al. Quantitative Computed Tomography Analysis, Airflow Obstruction, and Lung Cancer in the Pittsburgh Lung Screening Study , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[102] Jun She,et al. Chinese water-pipe smoking and the risk of COPD. , 2014, Chest.
[103] R. Casaburi,et al. Phenotype of normal spirometry in an aging population. , 2015, American journal of respiratory and critical care medicine.
[104] T. Ng,et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. , 2007, Archives of internal medicine.
[105] P. Frith,et al. Self management for patients with chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.
[106] F. Struik. Chronic non-invasive ventilation in COPD: where do we stand? , 2015 .
[107] T. Bregenzer,et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. , 2009, JAMA.
[108] T. Michele,et al. The safety of tiotropium--the FDA's conclusions. , 2010, The New England journal of medicine.
[109] P. J. Barnes,et al. Systemic manifestations and comorbidities of COPD , 2009, European Respiratory Journal.
[110] J. Wedzicha,et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.
[111] W. Stalman,et al. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands. , 1998, Journal of epidemiology and community health.
[112] A. Crockett,et al. Domiciliary oxygen for chronic obstructive pulmonary disease. , 2005, The Cochrane database of systematic reviews.
[113] P. Poole,et al. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. , 2019, The Cochrane database of systematic reviews.
[114] T. Meyer,et al. Noninvasive Positive Pressure Ventilation To Treat Respiratory Failure , 1994, Annals of Internal Medicine.
[115] Edwin K Silverman,et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. , 2013, The Lancet. Respiratory medicine.
[116] Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. , 1997, Bulletin of the World Health Organization.
[117] D. Halpin,et al. Palliative and end-of-life care for patients with respiratory disease , 2009 .
[118] D. Postma,et al. Chronic obstructive pulmonary disease. , 2002, Clinical evidence.
[119] B. Celli,et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. , 2006, Chest.
[120] M. Briel,et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. , 2013, JAMA.
[121] W. Dejsomritrutai,et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. , 2004, Chest.
[122] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[123] D. Postma,et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial , 2005, Thorax.
[124] R. Rodríguez-Roisín,et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. , 1998, American journal of respiratory and critical care medicine.
[125] W. Bailey,et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. , 1995, JAMA.
[126] M. Miravitlles,et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. , 1999, Chest.
[127] A. Høiseth,et al. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease , 2011, Thorax.
[128] tefan,et al. LONG-TERM TREATMENT WITH INHALED BUDESONIDE IN PERSONS WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO CONTINUE SMOKING , 2000 .
[129] Alice M Turner,et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. , 2015, The Lancet. Respiratory medicine.
[130] N. Metzdorf,et al. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial , 2014, BMC Pulmonary Medicine.
[131] B. Nordestgaard,et al. Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. , 2013, The Lancet. Respiratory medicine.
[132] G. Washko,et al. A randomised trial of lung sealant versus medical therapy for advanced emphysema , 2015, European Respiratory Journal.
[133] P. Jones,et al. Health status measurement in chronic obstructive pulmonary disease , 2001, Thorax.
[134] Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. , 1965, Lancet.
[135] M. Wysocki,et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. , 1995, The New England journal of medicine.
[136] R. Zuwallack,et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. , 2001, Chest.
[137] R. Masterton,et al. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. , 2001, International journal of antimicrobial agents.
[138] Ciro Casanova,et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.
[139] R. Ferrence,et al. Electronic Cigarettes for Smoking Cessation: A Systematic Review. , 2016, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[140] Berend C Stoel,et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.
[141] Meilan K. Han,et al. Pulmonary arterial enlargement and acute exacerbations of COPD. , 2012, The New England journal of medicine.
[142] K. Godfrey,et al. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. , 1991, BMJ.
[143] N. Anthonisen,et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.
[144] Gordon H. Guyatt,et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care , 2010, Canadian Medical Association Journal.
[145] Christopher E Brightling,et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.
[146] G. Valdivia,et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America , 2007, European Respiratory Journal.
[147] M. Tsukino,et al. Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease , 2011, International journal of chronic obstructive pulmonary disease.
[148] P. Poole,et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.
[149] Dirkje S Postma,et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study , 2000, The Lancet.
[150] E. Kerwin,et al. Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies , 2015, COPD.
[151] B. Rowe,et al. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials , 2003, BMJ : British Medical Journal.
[152] J. Curtis,et al. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease , 2006, Expert review of anti-infective therapy.
[153] R. Hancox,et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. , 2016, The Lancet. Respiratory medicine.
[154] P. Bower,et al. Effect of telehealth on quality of life and psychological outcomes over 12 months (Whole Systems Demonstrator telehealth questionnaire study): nested study of patient reported outcomes in a pragmatic, cluster randomised controlled trial , 2013, BMJ : British Medical Journal.
[155] T. Lasserson,et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.
[156] S. Parthasarathy,et al. Retrospective Assessment of Home Ventilation to Reduce Rehospitalization in Chronic Obstructive Pulmonary Disease. , 2015, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.
[157] D. Postma,et al. Relapse in FEV1 Decline After Steroid Withdrawal in COPD. , 2015, Chest.
[158] J. Garcia-Aymerich,et al. Wood smoke exposure and risk of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.
[159] C. Gatsonis,et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .
[160] R. Hoogenveen,et al. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach , 2010, European Respiratory Journal.
[161] Martijn A Spruit,et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.
[162] Thomas R Fanshawe,et al. Combined pharmacotherapy and behavioural interventions for smoking cessation. , 2016, The Cochrane database of systematic reviews.
[163] F. Abroug,et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial , 2001, The Lancet.
[164] J. Connett,et al. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. , 1996, American journal of respiratory and critical care medicine.
[165] S. Spencer,et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.
[166] E. A. V. van Eerd,et al. Smoking cessation for people with chronic obstructive pulmonary disease. , 2016, The Cochrane database of systematic reviews.
[167] J. Barberà,et al. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease , 1996, The Lancet.
[168] M. Fiore. A Clinical Practice Guideline for Treating Tobacco Use and Dependence A US Public Health Service Report , 2000 .
[169] Ulrike Held,et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index , 2009, The Lancet.
[170] L. Fabbri,et al. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents , 2010, Respiratory research.
[171] J. Hokanson,et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. , 2011, Chest.
[172] J. Wedzicha,et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.
[173] A. Anzueto,et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. , 2011, Archives of internal medicine.
[174] Stephanie J. C. Taylor,et al. Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology , 2011, Respiratory research.
[175] Toru Oga,et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. , 2002, Chest.
[176] P. Jones,et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.
[177] D. Matamis,et al. Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life. , 2014, Journal of critical care.
[178] Gorka Bastarrika,et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. , 2007, Chest.
[179] J. Bourbeau,et al. Inhaled tiotropium for stable chronic obstructive pulmonary disease. , 2000, The Cochrane database of systematic reviews.
[180] P. Frith,et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial , 2015, Thorax.
[181] K. Murphy,et al. The language of breathlessness. Use of verbal descriptors by patients with cardiopulmonary disease. , 1991, The American review of respiratory disease.
[182] P. Poole,et al. Tiotropium versus placebo for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.
[183] Meilan K. Han,et al. Clinical and Radiologic Disease in Smokers With Normal Spirometry. , 2015, JAMA internal medicine.
[184] P. Anderson,et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial , 2001, The Lancet.
[185] Hakan Günen,et al. Waterpipe tobacco smoking. , 2016, Tuberkuloz ve toraks.
[186] N. Cox,et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .
[187] M. Decramer,et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. , 2014, The New England journal of medicine.
[188] F. Speizer,et al. The relationship of nonspecific bronchial responsiveness to respiratory symptoms in a random population sample. , 1987, The American review of respiratory disease.
[189] Miwako Kobayashi,et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices , 2019, MMWR. Morbidity and mortality weekly report.
[190] I. Stiell,et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. , 2003, The New England journal of medicine.
[191] F. Martinez,et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.
[192] R. Rodríguez-Roisín,et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. , 2011, The Cochrane database of systematic reviews.
[193] B. O'connor,et al. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD , 2008, Thorax.
[194] J. Walusiak‐Skorupa,et al. Faculty Opinions recommendation of COPD in never smokers: results from the population-based burden of obstructive lung disease study. , 2011 .
[195] F. Martinez,et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.
[196] J. Vestbo,et al. The prognostic importance of lung function in patients admitted with heart failure , 2010, European journal of heart failure.
[197] H A Vrooman,et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. , 1999, American journal of respiratory and critical care medicine.
[198] W. Vollmer,et al. Marijuana and chronic obstructive lung disease: a population-based study , 2009, Canadian Medical Association Journal.
[199] E. Akl,et al. Effects of water-pipe smoking on lung function: a systematic review and meta-analysis. , 2011, Chest.
[200] P. Jones,et al. Oral theophylline for chronic obstructive pulmonary disease. , 2002, The Cochrane database of systematic reviews.
[201] J. Wedzicha,et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.
[202] J. Kai,et al. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. , 2015, Health technology assessment.
[203] Y. Kim,et al. The Effectiveness of Anti-leukotriene Agents in Patients with COPD: A Systemic Review and Meta-analysis , 2015, Lung.
[204] G. Michaud,et al. Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial. , 2016, JAMA.
[205] R. Pauwels,et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.
[206] R. Cavallazzi,et al. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies , 2011, Thorax.
[207] Andrew J. White,et al. Chronic obstructive pulmonary disease • 6: The aetiology of exacerbations of chronic obstructive pulmonary disease , 2003, Thorax.
[208] M. Ezzati. Indoor air pollution and health in developing countries , 2005, The Lancet.
[209] J. Yim,et al. Use of inhaled corticosteroids and the risk of tuberculosis , 2013, Thorax.
[210] A. Anzueto,et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. , 2000, Chest.
[211] J. Wedzicha,et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.
[212] Hospice. National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for quality palliative care, executive summary. , 2004, Journal of palliative medicine.
[213] J. Wedzicha,et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.
[214] P. Davies,et al. Tuberculosis, bronchiectasis and chronic airflow obstruction , 2010, Respirology.
[215] Stephan von Haehling,et al. Cachexia as a major underestimated and unmet medical need: facts and numbers , 2010, Journal of cachexia, sarcopenia and muscle.
[216] M. Decramer,et al. High Doses of Vitamin D to Reduce Exacerbations in Chronic Obstructive Pulmonary Disease: A Randomized Trial , 2012 .
[217] Hayden McRobbie,et al. E-cigarettes: an evidence update. A report commissioned by Public Health England. , 2015 .
[218] Shaf Keshavjee,et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[219] D. Mannino,et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study , 2007, The Lancet.
[220] T. Lasserson,et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.
[221] Robert Paine,et al. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. , 2016, The New England journal of medicine.
[222] K. Rabe,et al. Complex chronic comorbidities of COPD , 2008, European Respiratory Journal.
[223] A. Schols,et al. The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review , 2016, COPD.
[224] J. Soriano,et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities , 2009, Thorax.
[225] David G. Anderson,et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[226] D. Mannino,et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD , 2008, European Respiratory Journal.
[227] J. Hallas,et al. Gastro‐esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease , 2015, Respirology.
[228] A. Hansell,et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. , 2005, Chest.
[229] G. Pledger,et al. Tiotropium Respimat inhaler and the risk of death in COPD. , 2013, The New England journal of medicine.
[230] E. Regan,et al. Impact of self-reported Gastroesophageal reflux disease in subjects from COPDGene cohort , 2014, Respiratory Research.
[231] R. Sansores,et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.
[232] G. Zeng,et al. Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease. , 2004, Chinese medical journal.
[233] M. Decramer,et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study , 2013, European Respiratory Journal.
[234] G. Diette,et al. Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease. , 2015, American journal of respiratory and critical care medicine.
[235] C. Jenkins,et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. , 2009, Chest.
[236] I. Tager,et al. Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. , 1995, American journal of respiratory and critical care medicine.
[237] P. Plant,et al. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial , 2000, The Lancet.
[238] T. Troosters,et al. Increasing implementation and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement , 2016, European Respiratory Journal.
[239] M. Cazzola,et al. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.
[240] Eliane Cristina Zacarias,et al. Efeito da teofilina associada ao beta2-agonista inalatório de curta ou longa duração, em pacientes com doença pulmonar obstrutiva crônica estável: revisão sistemática , 2007 .
[242] H. Tange,et al. Early detection of COPD in general practice: implementation, workload and socioeconomic status. A mixed methods observational study , 2013, Primary Care Respiratory Journal: Journal of the General Practice Airways Group.
[243] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[244] L. Edwards,et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. , 2013, Respiratory medicine.
[245] E. V. van Rikxoort,et al. Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. , 2015, The New England journal of medicine.
[246] R. Ferrari,et al. Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction. , 2013, International journal of cardiology.
[247] N. Team. Chronic obstructive pulmonary disease in over 16s: diagnosis and management , 2018 .
[248] K. Nichol,et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. , 1994, The New England journal of medicine.
[249] M. Hamarshi,et al. Accuracy of Clinical Scores and Antibody Testing in the Diagnosis of HIT , 2012 .
[250] Brian J Smith,et al. Lung volume reduction surgery for diffuse emphysema. , 2016, The Cochrane database of systematic reviews.
[251] C. Whitney,et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2014, MMWR. Morbidity and mortality weekly report.
[252] A. Corrado,et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients , 2002, European Respiratory Journal.
[253] Michael Brauer,et al. Associations of ambient air pollution with chronic obstructive pulmonary disease hospitalization and mortality. , 2013, American journal of respiratory and critical care medicine.
[254] N. Chavannes,et al. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.
[255] R. Stockley,et al. Augmentation Therapy for α1 Antitrypsin Deficiency: A Meta-Analysis , 2009, COPD.
[256] Phung Anh Nguyen,et al. Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly , 2013, Comput. Methods Programs Biomed..
[257] N. Anthonisen,et al. Mortality in COPD: role of comorbidities , 2006, European Respiratory Journal.
[258] A. Ionescu,et al. What community measurements can be used to predict bone disease in patients with COPD? , 2008, Respiratory medicine.
[259] C. Roberts,et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit , 2015, European Respiratory Journal.
[260] S. Ginsburg,et al. Bronchodilator Delivery in Acute Airflow Obstruction , 2017 .
[261] K. Rabe,et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. , 2011, The New England journal of medicine.
[262] David M. Shade,et al. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. , 2016, The New England journal of medicine.
[263] B. Smith,et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.
[264] T. Seemungal,et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. , 2008, American journal of respiratory and critical care medicine.
[265] M. Antonelli,et al. Noninvasive vs. conventional mechanical ventilation in patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomized trial , 2002, Intensive Care Medicine.
[266] Philippe Ravaud,et al. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data , 2008, The Lancet.
[267] W. Dupont,et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. , 1994, The Journal of infectious diseases.
[268] P. Calverley,et al. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.
[269] A. Ionescu,et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.
[270] J. Bourbeau,et al. Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease , 2007, Annals of Internal Medicine.
[271] S. Suissa,et al. Inhaled corticosteroids and the risks of diabetes onset and progression. , 2010, The American journal of medicine.
[272] I. Pavord,et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. , 2015, The Lancet. Respiratory medicine.
[273] J. Barberà,et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial , 2013, European Respiratory Journal.
[274] K. N. Maranetra,et al. Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. , 2003, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[275] M. V. Lopez Varela,et al. Development of a simple screening tool for opportunistic COPD case finding in primary care in Latin America: The PUMA study , 2016, Respirology.
[276] D. Simel,et al. Does the clinical examination predict airflow limitation? , 1995, JAMA.
[277] Anne Holland,et al. Pulmonary Rehabilitation Exercise Prescription in Chronic Obstructive Pulmonary Disease: Review of Selected Guidelines: AN OFFICIAL STATEMENT FROM THE AMERICAN ASSOCIATION OF CARDIOVASCULAR AND PULMONARY REHABILITATION. , 2016, Journal of cardiopulmonary rehabilitation and prevention.
[278] L. Edwards,et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease , 2012, Thorax.
[279] Stefano Guerra,et al. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study , 2007, The Lancet.
[280] R. Holle,et al. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences‐Comorbidities Network Study , 2017, American journal of respiratory and critical care medicine.
[281] N. Zhong,et al. Lung Function and Incidence of Chronic Obstructive Pulmonary Disease after Improved Cooking Fuels and Kitchen Ventilation: A 9-Year Prospective Cohort Study , 2014, PLoS medicine.
[282] Nicolas Roche,et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. , 2009, Chest.
[283] R. Perera,et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. , 2013, The Cochrane database of systematic reviews.
[284] M. Scorsetti,et al. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. , 2015, American journal of respiratory and critical care medicine.
[285] J. Crowley,et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. , 1996, American journal of respiratory and critical care medicine.
[286] Dependence Update Panel,et al. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. , 2008, American journal of preventive medicine.
[287] Y. Lacasse,et al. Nocturnal noninvasive positive pressure ventilation in stable COPD: a systematic review and individual patient data meta-analysis. , 2014, Respiratory medicine.
[288] H. Hoogsteden,et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.
[289] J. Collet,et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. , 1997, American journal of respiratory and critical care medicine.
[290] Dave Singh,et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial , 2016, The Lancet.
[291] J. Hallas,et al. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease , 2014, Thorax.
[292] Edwin K Silverman,et al. Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk. , 2015, Annals of the American Thoracic Society.
[293] H. Sørensen,et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis , 2012, Thorax.
[294] P. Enright,et al. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications , 2012, Thorax.
[295] S. D. Lee,et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. , 2012, Respiratory medicine.
[296] E. Bateman,et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT) , 2015, Respiratory Research.
[297] Y. Oh,et al. Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease , 2015, International journal of chronic obstructive pulmonary disease.
[298] C. Bausewein,et al. Levodropropizine in the Management of Cough Associated with Cancer or Nonmalignant Chronic Disease–A Systematic Review , 2011, Journal of pain & palliative care pharmacotherapy.
[299] G. Guyatt,et al. A measure of quality of life for clinical trials in chronic lung disease. , 1987, Thorax.
[300] T. Seemungal,et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.
[301] J. Vonk,et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study , 2014, Thorax.
[302] N. Roche,et al. High-risk patients following hospitalisation for an acute exacerbation of COPD , 2013, European Respiratory Journal.
[303] G. Criner,et al. Surgical Approaches to Treating Emphysema: Lung Volume Reduction Surgery, Bullectomy, and Lung Transplantation , 2015, Seminars in Respiratory and Critical Care Medicine.
[304] J. Wedzicha,et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease , 1993, The Lancet.
[305] A. Dirksen,et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiency , 2009, European Respiratory Journal.
[306] Stefano Guerra,et al. Asthma as a risk factor for COPD in a longitudinal study. , 2004, Chest.
[307] J. van der Palen,et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. , 2002, American journal of respiratory and critical care medicine.
[308] B. Celli,et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. , 2000, Chest.
[309] R. Wood‐Baker,et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.
[310] D. Slebos,et al. Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial , 2011, The Lancet.
[311] T. Todisco,et al. Mild prematurity and respiratory functions , 2005, European Journal of Pediatrics.
[312] S. Antoniu,et al. Hospitalizations and mortality in the Lung Health Study , 2002, Expert review of pharmacoeconomics & outcomes research.
[313] Edwin K Silverman,et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.
[314] M. Jit,et al. Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. , 2015, Health technology assessment.
[315] S. Leu,et al. Reply: FEV1 can be associated with reduced values after vigorous exercise in healthy adolescents. , 2015, Annals of the American Thoracic Society.
[316] M. Puhan,et al. Mortality of patients with COPD participating in chronic disease management programmes: a happy end? , 2014, Thorax.
[317] E. Kerwin,et al. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.
[318] C. Cates,et al. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. , 2015, The Cochrane database of systematic reviews.
[319] Stefano Nava,et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. , 2014, The Lancet. Respiratory medicine.
[320] H. Moldofsky,et al. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. , 2015, The American review of respiratory disease.
[321] P. Poole,et al. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. , 2017, The Cochrane database of systematic reviews.
[322] Grant D. Huang,et al. A Comprehensive Care Management Program to Prevent Chronic Obstructive Pulmonary Disease Hospitalizations , 2012, Annals of Internal Medicine.
[323] A. Thomson,et al. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. , 1993, Thorax.
[324] M. Martínez-García,et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.
[325] Sally J. Singh,et al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial , 2014, BMJ : British Medical Journal.
[326] D. Au,et al. A randomized trial to improve communication about end-of-life care among patients with COPD. , 2012, Chest.
[327] D. Niewoehner,et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. , 1999, The New England journal of medicine.
[328] B. Ternestedt,et al. “The unpredictable death”—The last year of life for patients with advanced COPD: Relatives' stories , 2014, Palliative and Supportive Care.
[329] David O Wilson,et al. Association of radiographic emphysema and airflow obstruction with lung cancer. , 2008, American journal of respiratory and critical care medicine.
[330] S. Rennard,et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. , 2011, Chest.
[331] J. Wedzicha,et al. Beta-blockers in COPD: time for reappraisal , 2016, European Respiratory Journal.
[332] T. Welte,et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.
[333] Thierry Troosters,et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. , 2013, American journal of respiratory and critical care medicine.
[334] R. Rodríguez-Roisín,et al. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. , 2016, Chest.
[335] L. Stead,et al. Physician advice for smoking cessation. , 2004, The Cochrane database of systematic reviews.
[336] J. Toral,et al. Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.
[337] David Gur,et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. , 2011, American journal of respiratory and critical care medicine.
[338] C. Nordeen. Use of Inhaled Corticosteroids in Patients With COPD and the Risk of TB and Influenza: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2014 .
[339] O. Johnell,et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler® , 2002, European Respiratory Journal.
[340] Y. Kuo,et al. Association of Psychological Disorders With 30-Day Readmission Rates in Patients With COPD. , 2016, Chest.
[341] Nicola A Hanania,et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. , 2011, Radiology.
[342] G. McLennan,et al. A randomized study of endobronchial valves for advanced emphysema. , 2010, The New England journal of medicine.
[343] C. Janson,et al. The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.
[344] Erratum: reduced bone density and vertebral fractures in smokers. men and COPD patients at increased risk. , 2015, Annals of the American Thoracic Society.
[345] M. Decramer,et al. Bronchodilator responsiveness in patients with COPD , 2008, European Respiratory Journal.
[346] P. Schweitzer,et al. Relationship of ventricular ectopy to nocturnal oxygen desaturation in patients with chronic obstructive pulmonary disease. , 1985, The American journal of medicine.
[347] S. Cendon,et al. Effect of theophylline associated with short-acting or long-acting inhaled beta2-agonists in patients with stable chronic obstructive pulmonary disease: a systematic review. , 2007, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.
[348] P. Kvale,et al. Predischarge bundle for patients with acute exacerbations of COPD to reduce readmissions and ED visits: a randomized controlled trial. , 2015, Chest.
[349] M. Velloso,et al. Evaluation of effects of shoulder girdle training on strength and performance of activities of daily living in patients with chronic obstructive pulmonary disease , 2013, International Journal of COPD.
[350] D. Postma,et al. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. , 2007, Chest.
[351] J. Steurer,et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. , 2009, The Cochrane database of systematic reviews.
[352] P. Jones,et al. Creating scenarios of the impact of copd and their relationship to copd assessment test (CAT™) scores , 2011, BMC pulmonary medicine.
[353] C. Jenkins,et al. Cardiovascular events in patients with COPD: TORCH Study results , 2010, Thorax.
[354] Sally J. Singh,et al. Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis. , 2015, Health technology assessment.
[355] Marco Lodi,et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. , 2011, Respiratory medicine.
[356] M. Decramer,et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. , 2013, The Lancet. Respiratory medicine.